Best Diversified Pharmaceuticals Companies in Massachusetts, United States
The 75 best Diversified Pharmaceuticals companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Agenusbio.
Ranked: Best Diversified Pharmaceuticals companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Agenusbio Developer of immunotherapies to treat cancer 60Funding top 20%Tech top 34%Product top 35%Market top 37% All 11 signals ▾Fundingtop 20% Techtop 34% Producttop 35% Markettop 37% Moattop 44% Partnerstop 45% Fin. healthtop 48% Growthtop 50% Newsbottom 47% Talentbottom 40% Globalbottom 39% Funding: Raised $441M across 12 rounds · 12 rounds over 17 yrs (0.7/yr) Tech: 41 technologies across 6/8 capability areas · Cloud: Cloudflare, Fastly rank vs industry peers · Fliar Intelligence Index 60/100 | $441M | 12 mo ago | 533 | Garo Armen Chairman & CEO | — | — |
| 2 | Laronde Developer of RNA therapeutics | $440M | 57 mo ago | 116 | — | — | — |
| 3 | Ziopharm Oncology Develops immunotherapies for the treatment of cancer and autoimmune diseases | $377M | 81 mo ago | 36 | Kevin Boyle CEO | 160 patents Isophosphoramide mustard salt prodrugs for oral cancer therapy, especially glioblastoma. | — |
| 4 | Senda Biosciences Manufacturer of drugs for multiple therapeutic areas | $266M | 46 mo ago | 102 | Fabrice Chouraqui CEO | 56 patents Ionizable lipid nanoparticles for mRNA delivery and AHR antagonist small‑molecule therapeutics | — |
| 5 | Centessa Pharmaceuticals Developer of therapeutic programs addressing unmet needs in various disease areas | $250M | 64 mo ago | 83 83 → 157 (+89%) | — | — | — |
| 6 | Blue Rock Therapeutics Stem cell therapies for cardiovascular and neurological diseases | $225M | 114 mo ago | 138 | — | — | — |
| 7 | Jnana Therapeutics Company developing a drug discovery platform for targeting the solute carrier (SLC) family of transporters | $207M | 43 mo ago | 10 | Joanne Kotz Co-Founder & President | — | — |
| 8 | Acceleron Pharma Developer of protein therapeutics to treat cancer and rare blood disorders | $138M | 109 mo ago | 312 | — | 1,929 patents Therapeutic protein biologics targeting pulmonary hypertension and systemic sclerosis pathways | — |
| 9 | Pieris Pharmaceuticals Therapeutics based on recombinant engineered lipocalin mimics | $119M | 59 mo ago | 127 | — | — | — |
| 10 | EdenRoc R&D company focused on manufacturing of drugs for multiple therapeutic areas | $100M | 19 mo ago | 12 | — | — | — |
| 11 | Rectify Pharma Manufacturer of drugs for multiple therapeutic purposes | $100M | 56 mo ago | 31 | Jonathan Moore Founder | — | — |
| 12 | Navitor Developing therapeutics for age related, rare and genetic diseases by targeting the central regulator of… | $99M | 73 mo ago | 15 | — | 8 patents Ink-jet/ink-roller self-inking marking devices and adjustable card reel clip mechanisms | — |
| 13 | Imbria Pharmaceuticals Provider of therapeutics solution by translation the cellular metabolism | $90M | 7 mo ago | 4 | David-Alexandre Gros Co-Founder & CEO | 161 patents Metabolic modulators for cardiac, renal and fibrotic disease therapy using trimetazidine derivatives | — |
| 14 | Anji Pharmaceuticals Developer of peptides for treatment of hypercholesterolemia | $70M | 56 mo ago | 12 | — | — | — |
| 15 | NextRNA Developer of RNA-targeted therapeutics for multiple areas | $56M | 51 mo ago | 32 | Leon Lamas Co-Founder | — | — |
| 16 | Pinteon Therapeutics Company focused on the discovery and development of therapies targeting therapeutics for cancer, CNS and… | $55M | 53 mo ago | 8 | Martin Jefson CEO | — | — |
| 17 | Viva Tides Manufacturer of oligonucleotides therapeutics | $54M | 2 mo ago | — | Keming Zhou Founder & CEO | — | — |
| 18 | Dyax Global pharmaceutical leader committed to better health and a brighter future | $50M | 214 mo ago | 151 | — | 1,239 patents Therapeutics and diagnostics targeting plasma kallikrein and contact activation pathways for hereditary angioedema | — |
| 19 | SciFluor Innovative therapeutics for ophthalmology, fibrosis, and neurology using fluorine chemistry | $50M | 61 mo ago | 2 | — | — | — |
| 20 | Adnexus Discovers, develops, and distributes therapeutic class of biologics for treatment of oncology, immunology… | $42M | 226 mo ago | 58 | — | — | — |
| 21 | Restorbio Reviews beauty products, ingredients, and promotes informed skincare, hair, and body choices | $40M | 102 mo ago | 25 | — | 4 patents Pharmaceutical combination therapies and immune‑enhancing drug formulations | — |
| 22 | Animol Discovery R&D company focused on manufacturing drugs for multiple therapeutic areas | $34M | 17 mo ago | 20 | Philip Austin Co-founder and Member of Board of Directors | 11 patents Veterinary JAK inhibitor drugs and cyclic depsipeptide antiparasitic therapeutics | — |
| 23 | Anchor Therapeutics Targeted small peptide therapeutics for metabolic and cardiovascular diseases. | $30M | 190 mo ago | 3 | — | — | — |
| 24 | Harvard Apparatus Regenerative Technology Biotechnology company using a patient's own stem cells to regenerate organ tissue | $29M | 5 mo ago | 8 | Jerry He Chairman and CEO | 33 patents Regenerative scaffolds for hollow organ tissue engineering and scar reduction | — |
| 25 | Arisaph Biopharmaceutical company focused on developing therapies for cardiometabolic diseases and cancer | $26M | 129 mo ago | — | Christopher Kiritsy CEO & President | — | — |
| 26 | Syndexa Treatment for endoplasmic reticulum stress related metabolic diseases | $25M | 182 mo ago | — | Teo Uysal President & CEO | — | — |
| 27 | Surface Logix Small molecule therapeutics for metabolic and cardiovascular disorders | $24M | 191 mo ago | 35 | — | 152 patents Small-molecule therapeutics for kinase and lipid metabolism targets with enhanced pharmacokinetics | — |
| 28 | Bionaut Pharmaceuticals Develops small molecule drugs for cancer and inflammation | $23M | 250 mo ago | — | Mehran Khodadoust Co-Founder & Managing Director | — | — |
| 29 | Neutrolis R&D company focused on manufacturing of drugs for multiple therapeutic areas | $23M | 15 mo ago | 9 | Abdul Hakkim Co-Founder | 91 patents Engineered DNase enzymes for therapeutic nucleic acid degradation and biomanufacturing applications | — |
| 30 | Padlock Therapeutics R&D company focused on manufacturing of drugs for multiple therapeutic areas | $23M | 138 mo ago | 5 | — | — | — |
| 31 | Xenetic Biopharmaceutical company advancing immune-oncology technologies for high-value cancer indications | $19M | 44 mo ago | 4 | — | — | — |
| 32 | Vertex Pharmaceuticals Developer of drugs for the treatment of multiple disorders | $16M | 196 mo ago | 5,400 5,400 → 6,397 (+18%) | Joshua Boger Founder | — | — |
| 33 | KalVista Therapies for hereditary angioedema and diabetic macular edema based on small molecule plasma kallikrein… | $13M | 131 mo ago | 118 118 → 273 (+131%) | — | — | — |
| 34 | Orthogon Therapeutics Developing a pipeline of therapeutics for a range of disease indications | $12M | 2 mo ago | 3 | Ali Munawar Founding CEO | — | — |
| 35 | Cequent Pharmaceuticals Pioneering RNAi therapeutics for diverse diseases, including cancer and inflammatory conditions | $12M | 199 mo ago | — | Johannes Fruehauf ex-President | — | — |
| 36 | NKT Therapeutics Website setup tutorials for domain configuration and website appearance | $12M | 142 mo ago | 1 | — | — | — |
| 37 | Permeon Biologics Develops a panel of human proteins | $6M | 174 mo ago | — | John Ripple ex-CEO | — | — |
| 38 | MAKScientific Targeting the endocannabinoid system for the treatment of metabolic disorders, pain, addiction, and… | $6M | 13 mo ago | — | Alexandros Makriyannis Co-Founder | 22 patents Therapeutic small‑molecule drugs and manufacturing processes for addiction, cannabinoid toxicity, and fibrosis treatments. | — |
| 39 | pacDNA Developer of oligonucleotide enhancer technology for clinical-stage therapeutic asset development | $2M | 45 mo ago | — | Carl Lebel Chief Executive Officer | — | — |
| 40 | DeuteRx Improving racemic small molecule marketed drugs and drug candidates intended for patients across multiple… | $2M | 117 mo ago | 6 | — | 101 patents Deuterated CNS drug compounds and solid forms for improved pharmacokinetics | — |
| 41 | Proterris Developing carbon monoxide therapeutics for transplant, nephrology, pulmonary, and oncology applications | $2M | 82 mo ago | 5 | Jeffrey Wager Co-Founder & CEO | 28 patents Therapeutics enhancing organ/tissue function and transplant longevity, including CO‑releasing drugs. | — |
| 42 | Prothelia R&D company focused on manufacturing recombinant drugs for multiple therapeutic areas | $2M | 189 mo ago | 7 | Brad Hodges Founder | — | — |
| 43 | Piper Therapeutics Pre-clinical drug discovery company focused on higher order pathways that govern immune and inflammatory… | $1M | 121 mo ago | — | Russ Wilcox CEO | — | — |
| 44 | Innovation Pharmaceuticals Developer of small molecule therapies for indications in oncology, dermatology and infectious diseases | $1M | 92 mo ago | 4 | Leo Ehrlich CEO | — | — |
| 45 | Targeted Cell Therapies Developing drugs using proprietary delivery technology platform for the treatment of rare disease… | $500K | 228 mo ago | 4 | Ed Ginns Founder & CEO | — | — |
| 46 | Senolytic Therapeutics Developer of senolytic drugs for fibrosis, cancer and age related diseases | $500K | 88 mo ago | — | Marc Ramis Castelltort Co-Founder and Board Member | — | — |
| 47 | BYOMass R&D based company focused on manufacturing of small molecule drugs for multiple therapeutic areas | $355K | 81 mo ago | 2 | — | 20 patents Therapeutic antibodies targeting activin/GDF15 pathways for hematologic disease treatment | — |
| 48 | VS Health Group Provider of health solutions and services through strategic planning, corporate account management, and payer… | $240K | 26 mo ago | — | Jeffrey W Martini CEO | 9,820 patents Cell-based immunotherapies, targeted PET imaging agents, and regenerative biomaterial technologies. | — |
| 49 | PafosPharma Developer of novel medications targeting the endocannabinoid system for therapeutic use | $225K | 87 mo ago | — | Alexandros Makriyannis Founder | — | — |
Top 12 Diversified Pharmaceuticals companies in Massachusetts
#1
Series A · Woburn, Massachusetts · founded 2025$54Mraised▾
Manufacturer of oligonucleotides therapeutics. It specializing in developing extrahepatic RNA-targeting therapeutics. The company aims to overcome traditional limitations by delivering siRNA and antisense oligonucleotides to tissues beyond the liver, such as muscles and the nervous system, for treating chronic diseases.
- Apr 2026Series A$54M
#2
Public · Lexington, Massachusetts · founded 1994 · 533 employees$440.7Mraised▾
Developer of immunotherapies to treat cancer. The company's portfolio consists of bio-engineered therapies targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
- Jun 2025Post IPO—
- Jul 2020Post IPO$35M
- Jan 2019Post IPO$30M
- Oct 2018Post IPO$40M
#3
Series B · Boston, Massachusetts · founded 2014 · 4 employees$90.2Mraised▾
Imbria Pharmaceuticals provides therapeutics solution by translation the cellular metabolism. It is involved in providing transformative medicine, by altering the cellular metabolism and mitochondrial function.
- Nov 2025Series B—
- Mar 2025Series B$66.7M
- Jul 2019Series B$50M
- Jul 2018Series B$40.2M
#4
Series A · Braintree, Massachusetts · founded 2012 · 3 employees$12.5Mraised▾
Developing a pipeline of therapeutics for a range of disease indications
- Apr 2026Series A$11M
- Dec 2024Series A$5.2M
- Nov 2021Series A$8M
- Mar 2018Series A$4.4M
#5
Public · Holliston, Massachusetts · founded 2012 · 8 employees$28.5Mraised▾
HRGN is a clinical-stage biotechnology company that specializes in regenerating organ tissue using a patient's own stem cells grown on a scaffold. They are focused on developing innovative solutions for patients with damaged organs due to cancer, trauma, birth defects, or other diseases. The company is led by an experienced team with a background in biotechnology, patient care, finance, and new product development.
- Dec 2025Post IPO$700K
- Jul 2025Post IPO$2M
- Apr 2024Post IPO$1.5M
- Apr 2023Post IPO$6M
#6
Series D · Cambridge, Massachusetts · founded 2016 · 12 employees$100.1Mraised▾
Operator of a biotechnology company intended to cultivate life sciences start-up companies. The company specializes in enabling the translation of top-tier academic and government science into technologies that provide novel and cutting-edge research tools, diagnostics and pharmaceuticals, thereby helping clients to address multiple biotech and healthcare markets.
- Nov 2024Series D$2.8M
- Jun 2022Series D$64.2M
- May 2021Series C$35.9M
#7
Series B · Boston, Massachusetts · founded 2019 · 20 employees$34Mraised▾
R&D company focused on manufacturing drugs for multiple therapeutic areas
- Jan 2025Series B$6.5M
- Nov 2024Series B$4M
- Jul 2022Series B$34M
#8
Series B · Cambridge, Massachusetts · founded 2017 · 9 employees$23.1Mraised▾
R&D company focused on manufacturing of drugs for multiple therapeutic areas
- Feb 2025Series B$965K
- Dec 2021Series B$23.1M
- May 2020Grant (prize money)$251.7K
#9
Funding Raised · Boston, Massachusetts · founded 2004$5.6Mraised▾
MAKScientific is developing small molecule drugs to treat disease by targeting the endocannabinoid system, a key regulator of homeostasis. These targets include the known cannabinoid receptors (CB1 and CB2) as well as key enzymes involved in modulating the system including fatty acid amide hydrolase (FAAH), monoacylglyceral lipase (MGL), N-acylethanolamine-hydrolyzing amidase (NAAA), diacylglycerol lipase (DGL) as well as the cannabinoid transporter system. Its lead candidate AM6545 is a peripherally restricted CB1 receptor antagonist which is being developed to treat chronic liver disease and metabolic disorders. Also has preclinical drugs for neuropathy, multiple sclerosis, addiction and pain.
- May 2025Grant (prize money)$375K
- Feb 2025Grant (prize money)$375K
- Sep 2024Grant (prize money)$572.7K
- Jun 2023Grant (prize money)$320K
#10
Series C · Boston, Massachusetts · founded 2017 · 10 employees$207Mraised▾
Jnana Therapeutics , launched with a $50M series A funding round backed by a top-tier syndicate that included AbbVie Ventures and Pfizer R&D Innovate, is developing the first ever drug discovery platform that will be dedicated to the development of small molecules that target the solute carrier (SLC) family of transporters, which are the cell’s metabolic gates. The SLC group of membrane transport proteins includes over 400 members organized into 52 families. The company will be focusing on areas such as immunometabolism, lysosomal function and mucosal defense, and other important disease pathways where SLC transporters can prove to be novel targets for immuno-oncology, inflammatory disorders and neurological diseases.
- Nov 2022Series C$107M
- Aug 2021Series B$50M
- Dec 2017Series A$50M
- Seed—
#11
Series C · Cambridge, Massachusetts · founded 2019 · 102 employees$266Mraised▾
Manufacturer of drugs for multiple therapeutic areas
- Aug 2022Series C$123M
- Jun 2021Series B$98M
#12
Series B · Cambridge, Massachusetts · founded 2017 · 116 employees$440Mraised▾
Developer of RNA therapeutics. The company provides Endless RNA (eRNA) based therapeutics that allow in-vivo expression of proteins which can be used as medicines in multiple therapeutic areas and can be delivered through multiple routes of administration.
- Aug 2021Series B$440M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diversified Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.